Cost effectiveness of combination ipilimumab-nivolumab in advanced non-small-cell lung cancer.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institution: University of California San Diego
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3029332205
